Accenture CEO Julie Sweet has been diagnosed with early-stage breast cancer. With an excellent prognosis and a curable condition, she will undergo surgery and radiation treatment while continuing ...

Accenture CEO Julie Sweet has been diagnosed with early-stage breast cancer and the treatment is likely to last 12-16 weeks, according to a Moneycontrol report. However, the CEO will continue to ...

Accenture Chief Executive Officer Julie Sweet has been diagnosed with early-stage breast cancer and the treatment is likely to last 12-16 weeks, Moneycontrol has learnt. “I was very recently ...

Today, Accenture plc (NYSE:ACN), a $243 billion market cap technology consulting giant, disclosed an update on the health of Julie Sweet, the company's Chair and Chief Executive Officer.

Good morning. Accenture CEO Julie Sweet announced yesterday that her breast cancer has come back, noting in a memo to staff that “the prognosis from my doctor is excellent; the cancer was caught ...

Accenture CEO Julie Sweet was praised this week for her openness regarding a breast cancer diagnosis, which also gave rare insight into how executives disclose their life-altering health news. Sweet, ...

Mr. James O. (Jimmy) Etheredge, former Chief Executive Officer - North America of Accenture plc (NYSE:ACN), will join the board effective April 1, 2025. This development was disclosed in a recent ...

Accenture CEO Julie Sweet was praised this week for her openness regarding a breast cancer diagnosis, which also gave rare insight into how executives disclose their life-altering health news.